Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Savolitinib - AstraZeneca/Hutchison MediPharma

Drug Profile

Savolitinib - AstraZeneca/Hutchison MediPharma

Alternative Names: AZD-6094; HMP-504; HMPL-504; Volitinib

Latest Information Update: 04 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hutchison MediPharma
  • Developer AstraZeneca; Hutchison MediPharma; National Cancer Institute (USA); Samsung Medical Center
  • Class Antineoplastics; Imidazoles; Pyrazines; Pyrazoles; Pyridines; Small molecules; Triazines; Triazoles
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Renal cell carcinoma
  • Phase II Colorectal cancer; Gastric cancer; Lung cancer; Non-small cell lung cancer; Prostate cancer
  • Phase I CNS cancer; Solid tumours

Most Recent Events

  • 26 Nov 2019 AstraZeneca plans a phase I trial for Solid tumours (Monotherapy, Combination therapy, In adults, In the elderly, In volunteers) in USA in December 2019 (PO) (NCT04179071)
  • 17 Oct 2019 Phase-I clinical trials in Solid tumours (In volunteers, Combination therapy) in USA (PO) (NCT04118842)
  • 17 Oct 2019 Phase-I clinical trials in Solid tumours (Monotherapy, In volunteers) in USA (PO) (NCT04118842)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top